All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the fireside chat with our next company, Zenas BioPharma, and we have a CEO, Lonnie Moulder, here. Lonnie will give us a quick overview and then sit down with me for the chat. Lonnie.
Thank you, Roger. It's great to be here. We appreciate you all attending, hearing a little bit about Zenas today, and we'll be making some forward-looking statements, so I refer you to our SEC filings. This is the pipeline, and I think many of you are familiar with it. We have quite a bit going on across our future rheumatology and neuroimmunology franchises. Today, we'll focus mostly in on obexelimab, IgG4-related disease, which is an indication that we're pursuing with a BLA under review, a PDUFA date of May 27th next year, and an MAA also under review. We'll talk a little bit about the SunStone phase II-B lupus or SLE trial. I think Roger has some interest in discussing that. Then we'll probably skip to ZB021 because we have some near-term data for our oral IL-17 inhibitor that I think quite a few people have interest in.
So if we look at IgG4-RD, first of all, as the first launch indication for obexelimab, potentially by the middle of next year, we have a lot of activities underway that we'll discuss more in preparing for that launch. But I would say critical to this, so that you understand our positioning, is we believe this drug has the right balance of efficacy and safety. With its unique mechanism of action, it provides a lot of flexibility to clinicians in treating patients that are older and have a lot of comorbidities, and it's very convenient with a subcutaneous administration where patients can take this at home to manage their disease, which is a chronic disease. This is a disease where patients need to take the medication for years, because if they flare, not being controlled with medication, if they flare, it leads to organ damage over time and fibrosis.
The initiatives right now are really to prepare the marketplace. We've had our medical science liaisons in the field for scientific exchange purposes with key opinion leaders, investigators, and others, primarily in the rheumatology community. We just returned from the American College of Rheumatology meeting last week, where we had a great deal of exchange and market research ongoing that's really solidified our overall launch strategy. From a deployment standpoint, it's important that we target with our resources those clinicians that do most of the prescribing in this field, and we've identified through claims data that there are just over 7,000 healthcare professionals that should be targeted by our sales force and our other resources. The accounts that those clinicians practice in overall manage just over 90% of all IgG4-RD patients, and the requirement is that we deploy 45 sales representatives.
So to date, we have our marketing team in place, our market research team in place, market access team in place, medical science liaisons. We will supplement that, of course, with what we call strategic engagement personnel, nurse educators, and then the sales force, which will be hired approximately one quarter prior to launch, as listed here. So, at the ACR meeting, we followed up on the recent IgG4-RD symposium where new data was put forward. As you may recall, obexelimab was the subject of a large randomized phase III trial that we call INDIGO, and that was a 52-week trial. Following the randomized control period of that trial is a three-year open-label extension. So, at the symposium, and then following up at the ACR meeting, data were presented that looked at the next 52-week probability of flare protection, flare protection of approximately 90%.
So we are quite pleased to see that sustainability over time and a side effect profile that is similar to the 52-week period where the degree of serious adverse events and grade three infections was actually no greater than the placebo arm. So, a great data set. In addition, many of you know that there is a vaccine sub-study as part of that open-label extension study, and that is where certain clinical sites have the ability to pause obexelimab use, administer a vaccine, and it is either COVID, flu, or both, then restart after two weeks on obexelimab and assess antibody titers to flu and COVID. Noted here is the number of patients that attained the benchmark level of immunity that one would want to see. That is the flexibility I mentioned earlier with this molecule as an inhibitor instead of a depleter of B cells.
So that brought in a lot of attention with our team out at ACR. Moving briefly to obexelimab in SLE, which we will talk about in just a moment. As you know, there was a phase II-A study conducted by Xencor a number of years ago, and that phase II-A study gave us the proof of concept that this drug could be meaningful in lupus. In addition, the work that they did with deep sequencing showed a gene pattern or a set of patterns that could predict even greater responsiveness to the drug. So we are conducting the phase II-B SunStone trial in SLE, and we are looking at that biomarker strategy where it is an all-comer population, but all patients will be assessed for how the biomarker performs.
The data that we will be releasing later this quarter will be the MITT population, the BICLA measurement as the primary endpoint, the MITT population for SRI-4, really looking at both of those to determine what might make sense to bring into a phase III program. Then we will also look at the biomarker positive population for each of those two key endpoints, and then think about what type of phase III could be designed. Should it be an all-comer trial? Would it be an all-comer trial where we first test for biomarker in a hierarchy and then the overall population? Or will it be a biomarker-only driven trial where we select for biomarker-positive patients to begin with? All that will be decided once we have the results of the phase II-B study in a few weeks. I will wrap up here with our oral IL-17 inhibitor.
I think many of you are well aware of the first interleukin oral inhibitor out there. J&J is marketing an oral IL-17 peptide. As you know, IL-23 peptide, as you probably know, IL-17 has a lot of relevance in diseases that overlap with IL-23, but in particular, in rheumatic diseases, more bone as opposed to skin-oriented. We, as a company that are building a rheumatology franchise, are quite interested in advancing our IL-17 inhibitor into rheumatic diseases. First step, though, is how does this profile look relative to agents that are already approved, those being biologics? You've heard this before. Is there an opportunity to take a molecule that's smaller in size and might have greater penetration to the diseased tissue, whether that's skin layers or, as you see on the left, entheses, the synovial area?
What we conducted here was a mini pig study where we actually look at how do the target tissues pick up the drug compared to the drug concentration in plasma. On the left axis, it's really a ratio in percentages. You can see that across all those tissues, the concentration is actually greater than in the plasma. I think that amplifies what's on the right, what a small molecule looks like, ZB021, in size compared to whether it's a peptide inhibitor, an antibody, or a full IgG monoclonal antibody. We think there's an opportunity here to leverage the size of this molecule into certain diseases. For us, the way we've designed our current study is to look at those characteristics you want to in phase I. What is the exposure, the exposure relative to IC50 and IC90, safety, tolerability?
Can we make this happen with once-daily dosing? We've already indicated we believe we can, but we'll have the specifics on some of this here in a few weeks. Then think about where we go next, which is most likely a rheumatic disease as phase II proof of concept to then set up moving into phase III. With that, I'll sit down and join Roger over here.
Thank you, Lon. All right, so you have a couple things in the pipeline. Maybe we'll focus on the obexelimab in IgG4 first, maybe a little bit of SLE, and certainly we're going to talk about IL-17 as well. For the SLE, understanding it's under review, PDUFA date next year, early next year. How much you can tell us about the regulatory process, mid-cycle review, et cetera, and also the CMC side, how ready that is, understanding it's a single supplier?
Yeah. So for IgG4-related disease with obexelimab, obviously under active review, and some of this is statutory. There's a mid-cycle review, there's a late-cycle review, there's a time when label negotiations begin. We don't comment on specifics of regulatory review, but we're already through the mid-cycle review. You can do the calculation. It's the type of interaction that tells us that regardless of what you hear from the outside about the FDA, we know the rheumatology team is working hard. We have a lot of interaction. Along the way, there'll be manufacturing site inspections, drug supply, drug product, or drug substance, drug product, clinical sites, and the company itself is inspected. That's just normal process. All of that is going as expected. As I mentioned before, the PDUFA date is May 27th.
Okay.
As far as manufacturing CMC overall, we have a supply chain obviously in place for our current formulation, which we would anticipate for launch, which is a prefilled syringe. But we've also developed an auto-injector pen and conducted a bioequivalence trial that was successful comparing the auto-injector pen to the prefilled syringes. That auto-injector pen will be the subject of a supplemental BLA, an sBLA, that would be submitted just after the BLA is approved. We can't submit now. That would restart the clock. But the MAA to Europe contains the auto-injector pen as the first formulation. That's how far along that is, to give you a sense of all that. We have our commercial supplies ready, and we also have in place a U.S.-only supply chain that's already produced batches.
Excellent. Seems everything on track and then full speed ahead. All right. I just also came back from ACR, and we met that as well. So I was impressed how consistent the feedback I got from the rheumatologists in terms of their strong preference for the inhibitor over the depleter, and they have a lot of reasons. Maybe for Zenas' perspective, now you're about to launch the drug. How do you think about the initial ramp-up going to do, given we understand this is a rare disease, but well identified, but also you have approved the drug, already launched for a couple quarters. So how should we think about the ramp you will think now?
Yeah. We're not going to guide specific sales. I mean, that doesn't make a lot of sense early in a launch. What we're going to land on, and we'll do a call in the first half of next year, because right now for our quarters, we're not doing calls. We're issuing quarterly news releases, but we need to start doing calls. What we'll want to do is lay out to everyone what metrics we're going to make public and how long we'll make those public until it's obvious that what you're reporting each quarter is your revenue. So we're working through that now, what makes the most sense, new starts, payer coverage, those kind of things. As far as a specific ramp-up curve, that's not something I want to comment on this time. We have thoughts in mind. We've done our own internal forecasts, of course.
But let's get closer to the launch, and we'll tell you the metrics and how we're going to measure it, and then we'll report those out quarter by quarter.
Yeah, we'll stay tuned on that. Maybe just on one specific question that related to the patient flow. You have maybe have some patient treatment naive to any of the CD19, CD20 targeted therapy, or you have a patient currently on Rituxan as off-label or on the other CD19, Uplizna as a switcher. So how you think about those patient going to flow to the Albecco?
Yeah, this was on one of the slides. I skipped over it so we could talk about it here. But what we're hearing from clinicians is there's a number of opportunities, because they are quite favorable of this concept of an inhibitory approach instead of depleting a portion of the immune system repeatedly for the next several decades in these patients. So the thought is, of course, patients who are in flare, and some may refer to them as new patients. They could be newly diagnosed in an IgG4-RD flare, or they could be a patient that was diagnosed years ago and has been on therapy, off therapy, and now they're flaring again. So whether they're a brand new diagnosed patient or a previous patient, but in the moment they're in a flare, that's an obvious place to get started.
But the other area that they've mentioned frequently, because they like this concept of inhibition instead of continuous depletion, is a patient that may have received one of the depleting antibodies, whether anti-CD20 or anti-CD19, and they're coming up upon their next six-month infusion, because they're dosed every six months. And before a patient gets another infusion of one of those antibodies, they obviously see their clinician, and they have their labs done, and there's a clinical assessment, and then the infusion center has to be scheduled.
And in their minds, that was an ideal opportunity when it is that time for the patient to assess the patient to then just move to potentially obexelimab, where they can actually, in the moment, administer it in the office, write the prescription, and then through either our specialty pharmacy or through the hub that we put in place, the patients will be educated, and they will receive their case packs monthly from that point forward. So there are several interventions that physicians have in mind as to how they might start this in their patient population.
Excellent. Okay, great. Okay, I think that is the IgG4, and then you do have two data sets going to read out by the end of the year. One is also Obex in the SLE. The other one is you just mentioned IL-17, small molecule. On the SLE, I think you already public said that the bar on the SRI-4 or the BICLA is about low teens, high 20s.
High teens, low 20s.
High teens, low 20s. So that is a fair bar because that is what we have seen from the pipeline, also the standard of care. So how should we think about the biomarker? You have two metrics, right? So how much higher efficacy you want to see from the biomarker-driven population? Also, how big the biomarker population prevalence makes sense for you to pursue that population?
Yeah. Just to confirm what you said upfront here about the bar, there's no magical number. The approved drugs are in the teens. The best data sets out there on BICLA, which is our primary, are low 20s. I think the recent TLR7/8 data was an effect size that was in the 30s on SRI-4, but on BICLA, it was down in that range we're talking about. So high teens, low 20s is the range for the overall population. For the biomarker population, the way the biomarker is evaluated, we have the opportunity, because this is exploratory right now. This is not the phase III study, but we have the opportunity to actually toggle it. So we can look at the biomarker and the number of transcripts used, because this is really evaluating gene patterns. So you're using transcripts.
We can vary that and look at the impact of that on the effect size, but also the percentage of the population that show up positive with it. So we will toggle that and then optimize for what makes the most sense of the most effect size that impacts the most patients. So you can imagine the thought process and the analysis that goes into that, and then put that alongside of the overall population and decide where we would go with that. So I can't declare a number. Let's see what the data is and how we can optimize it, and whether it's meaningful enough to do a hierarchical phase III study where we would test biomarker then overall, or if it makes sense just to do a biomarker study.
As you know, especially in the oncology realm, how important that can be and how much value that can actually add to the ability for physicians to select the right patients. In lupus in particular, I mean, face it's a heterogeneous disease. There are different drivers in different lupus patients. What we're not looking at is an interferon signature. For certain mechanisms, I think interferon signature makes a lot of sense. This is a B-cell targeting mechanism. This is a bit different. But what if we can select those patients that have the most highest likelihood of responding? That adds a lot of value. Can that ultimately also be captured in price, and can it be captured in the market share penetration you're going to have? So we'll see. The data will be here shortly.
Awesome. One thing we noticed, just like you said, you're going to toggle these two metrics. This is kind of post hoc in terms of the data analysis. How confident that you can, once you have that data, you will have the conversation with the regulator, and then the cutoff, whatever the cutoff you choose in the phase II, going to be the phase III, inform the phase III?
Yeah. You move to phase III, and you're very thoughtful in your design. You give yourself some flexibility there to perform in a range. You build that into the study. There are steps with the FDA, of course. What we're doing is already available as a CLIA test. It exists with a commercial entity. We'll fine-tune it, and then in the case of moving into a clinical study, you have to do an investigational device exemption, just like you do with a biomarker in oncology, and ultimately it's a concurrent pre-market authorization, PMA, along with your, in this case, BLA. There's a regulatory path here that's well-worn, especially in oncology, and that's what we would do.
Okay. Wall Street still like the numbers. I think you know, you'll maximize the efficacy or the effect size, and then with the larger population. So any minimum numbers you would say in order to make this population or biomarker population sense? Right, effect size like a 10% higher than the all-comer, and then the population at least 30%-40%. So how much we should say that?
I don't have a number.
That's fair, right? You're definitely going to data-driven, right? So it will make sense. You're going to convince the street that's the right strategy you can pursue, right? Okay, so for the IL-17, a lot of the attention on the IL-17. It is a little bit early stage data. Why we should be excited about this dataset? Then the next step, you're going to choose the patient population. You already said that's the rheumatic disease, and then what's the any narrow down the indication selection?
Yeah. What's really exciting here is, although it's early data from a SAD, single ascending dose study, and a MAD, multiple ascending dose study, we have a mechanism that we know that works in multiple diseases. If we have a molecule that can impact that pharmacologic target in a meaningful way, even before we have patient data, I think that tells you probably have a drug. Question will be, how exciting it is, how does it compare to others? But out of the SAD/MAD results, if you're showing, we know what the potency is. If you're showing coverage of that with once daily dosing and well tolerated, you're going to have something that's going to make a difference in the disease, and then we'll go do the disease.
We'll do the first phase II proof of concept study, and the current thinking is that phase II could be the phase II for the registration program. From phase I, confirming the drug performs as it should, right exposure, once a day, covers the target as it should, it's tolerated, move to the phase II, have datasets potentially next year, and if that's positive, then you're going into phase III. I would say with a mechanism like this, in the market we already understand for IL-17, it's the type of thing where, yeah, we would go to what's probably the obvious first indication that follows the phase II, same disease. But I think for us, and I think the capital markets would support multiple phase III studies. I mean, that's how you build a franchise.
When you know a mechanism impacts many diseases, and there's a real desire for oral agents in these arenas, just as what's being shown by J&J with their IL-23 inhibitor. That's why we're excited about it.
Excellent. Okay, just lastly on the capital, the current cash runway, and then you have even more than the pipeline we discussed today. How much you are funded, and then what's next?
Sure. We finished the last quarter with just about $650 million on the balance sheet, and as we go forward, if we assume obexelimab is approved, we will have $75 million that should flow from our Royalty Pharma arrangement, our royalty financing deal. And we have the opportunity with Pharmakon to take another $75 million. With that would put us through the second quarter of 2029. So a really good cash position.
Excellent. Okay. Thank you, everyone. Thank you, Lon.
Thank you, Roger.